Last updated: Oct 15, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06324357 | 1, 2 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | HER2 -- tyrosine kinase inhibitor and antibody-drug conjugates |
| NCT06439771 | 2 | A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | Unknown mechanism |
| NCT05827081 | 3 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | CDK4/6 -- cyclin-dependent kinase 4/6 inhibitor |
| NCT07140172 | — | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery | Unknown mechanism |
| NCT06952803 | 3 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | PARP -- PARP inhibitor |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 111 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 |
| Memorial Sloan Kettering Cancer Center | 35 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 29 |
| The First Affiliated Hospital with Nanjing Medical University | 28 |
Countries/regions with the most active trial sites for breast cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 1, 2027 | NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | Her2 + GD2 + CD44v6 -- chimeric antigen receptor T cells (CAR-T) |
| Jun 2027 | NCT04861077 | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | Tumor hypoxia -- 18F-fluoromisonidazole PET with MRI (diagnostic imaging) |
| Jan 2027 | NCT07454668 | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases | HER2 -- antibody-drug conjugate (ADC) + stereotactic radiosurgery |
| Dec 15, 2026 | NCT07867262 | A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer | Estrogen receptor -- selective estrogen receptor degrader/modulator (SERD/SERM); Unknown mechanism (GDC-4198) |
| Dec 2026 | NCT07785856 | Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer | HER2 + RAGE -- antibody-drug conjugate (T-DXd) combined with RAGE inhibitor |
| Nov 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Regulatory T cells -- gene-edited cell therapy |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Oct 30, 2026 | NCT07310420 | A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | GnRH receptor -- ovarian suppression via luteinizing hormone release inhibition (GnRH agonist) |
You've seen the breast cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.